Q-omics provides the consensus-scored OTOP2 profile across patient tissues and cancer cell-line models. OTOP2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, OTOP2 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, OTOP2 RNA expression shows 8,733 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight LIHC, COAD, and ESCA as cancer lineages where OTOP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OTOP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OTOP2 survival associations across molecular data types. OTOP2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OTOP2 RNA expression–survival associations across cancer types. High OTOP2 expression shows unfavorable associations in LIHC, SKCM, UCEC and LUAD, but favorable associations in HNSC and TGCT. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify LIHC as the clearest survival context for OTOP2 RNA expression.
This table summarizes OTOP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for OTOP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OTOP2 shows lower tumor expression in COAD, READ, HNSC, KICH and STAD and higher tumor expression in LUSC. The COAD box plot shows higher OTOP2 RNA expression in normal versus tumor tissue (log2 FC = −6.721, t-test p < 0.001).
This table shows molecular features associated with OTOP2 in patient tissues and cancer cell lines. In patient samples, OTOP2 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, OTOP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
